Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease

Peripheral biomarkers of Alzheimer's disease (AD) reflecting early neuropathological change are critical to the development of treatments for this condition. The most widely used indicator of AD pathology in life at present is neuroimaging evidence of brain atrophy. We therefore performed a proteomic analysis of plasma to derive biomarkers associated with brain atrophy in AD. Using gel based proteomics we previously identified seven plasma proteins that were significantly associated with hippocampal volume in a combined cohort of subjects with AD (N = 27) and MCI (N = 17). In the current report, we validated this finding in a large independent cohort of AD (N = 79), MCI (N = 88) and control (N = 95) subjects using alternative complementary methods—quantitative immunoassays for protein concentrations and estimation of pathology by whole brain volume. We confirmed that plasma concentrations of five proteins, together with age and sex, explained more than 35% of variance in whole brain volume in AD patients. These proteins are complement components C3 and C3a, complement factor-I, γ-fibrinogen and alpha-1-microglobulin. Our findings suggest that these plasma proteins are strong predictors of in vivo AD pathology. Moreover, these proteins are involved in complement activation and coagulation, providing further evidence for an intrinsic role of these pathways in AD pathogenesis.

[1]  Chengjie Xiong,et al.  Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis , 2011, PloS one.

[2]  T. Welte,et al.  Circulating complement proteins in patients with sepsis or systemic inflammatory response syndrome , 1996, Clinical and diagnostic laboratory immunology.

[3]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[4]  Gunhild Waldemar,et al.  Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. , 2007, Archives of neurology.

[5]  Norman Relkin,et al.  Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease , 2007, Annals of neurology.

[6]  B. Horwitz,et al.  Volumetric magnetic resonance imaging in men with dementia of the Alzheimer type: Correlations with disease severity , 1993, Biological Psychiatry.

[7]  Nancy Reagan,et al.  Consensus Report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease" , 1998 .

[8]  Susan M Resnick,et al.  Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.

[9]  Eileen Daly,et al.  Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer’s disease , 2008, Journal of Neurology.

[10]  Kaj Blennow,et al.  Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients , 2003, Neuroscience Letters.

[11]  Nick C Fox,et al.  Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.

[12]  Albert Hofman,et al.  Fibrinogen Is Associated With an Increased Risk of Alzheimer Disease and Vascular Dementia , 2005, Stroke.

[13]  K. Mattila,et al.  Two-dimensional analysis of qualitative and quantitative changes in blood cell proteins in Alzheimer's disease: search for extraneuronal markers. , 1995, Applied and theoretical electrophoresis : the official journal of the International Electrophoresis Society.

[14]  Christos Davatzikos,et al.  Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment , 2012, NeuroImage.

[15]  S. Meri,et al.  Yin and Yang: complement activation and regulation in Alzheimer’s disease , 2003, Progress in Neurobiology.

[16]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[17]  Marilyn S. Albert,et al.  Research consent for cognitively impaired adults: recommendations for institutional review boards and investigators. , 2004, Alzheimer disease and associated disorders.

[18]  D. Bonifati,et al.  Role of complement in neurodegeneration and neuroinflammation. , 2007, Molecular immunology.

[19]  N Purandare,et al.  Biomarkers of cerebrovascular disease in dementia. , 2007, The British journal of radiology.

[20]  Christopher Clark,et al.  Disease-modifying therapies for Alzheimer disease , 2007, Neurology.

[21]  C. Jack,et al.  Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.

[22]  Giovanni B. Frisoni,et al.  Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .

[23]  David A. Bennett,et al.  Mixed brain pathologies account for most dementia cases in community-dwelling older persons , 2007, Neurology.

[24]  Alan C. Evans,et al.  Automatic "pipeline" analysis of 3-D MRI data for clinical trials: application to multiple sclerosis , 2002, IEEE Transactions on Medical Imaging.

[25]  S Lovestone,et al.  Biomarkers for disease modification trials--the innovative medicines initiative and AddNeuroMed. , 2007, The journal of nutrition, health & aging.

[26]  Nick C. Fox,et al.  Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease: Cross-validation of BSI, SIENA and SIENAX , 2007, NeuroImage.

[27]  Nick C Fox,et al.  Amnestic Mild Cognitive Impairment: Structural MR Imaging Findings Predictive of Conversion to Alzheimer Disease , 2008, American Journal of Neuroradiology.

[28]  S. Lovestone,et al.  Proteome-based plasma biomarkers for Alzheimer's disease. , 2006, Brain : a journal of neurology.

[29]  Magda Tsolaki,et al.  The AddNeuroMed framework for multi‐centre MRI assessment of Alzheimer's disease : experience from the first 24 months , 2011, International journal of geriatric psychiatry.